Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
36,346,799
-
Share change
-
+2,626,050
-
Total reported value
-
$636,820,871
-
Put/Call ratio
-
69%
-
Price per share
-
$17.52
-
Number of holders
-
116
-
Value change
-
+$70,521,771
-
Number of buys
-
72
-
Number of sells
-
36
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q4 2020
As of 31 Dec 2020,
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) was held by
116 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,346,799 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, Redmile Group, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., EVENTIDE ASSET MANAGEMENT, LLC, STATE STREET CORP, VANGUARD GROUP INC, Acuta Capital Partners, LLC, CITADEL ADVISORS LLC, Ikarian Capital, LLC, and Vivo Capital, LLC.
This page lists
117
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.